Andlauer Healthcare Group (AND) Q4 2024 earnings summary

Executive summary

• Achieved record consolidated revenue of CAD 650.5 million for the year, driven by strong Canadian operations despite U.S. headwinds.

• Q4 2024 revenue was CAD 168.3 million, down 0.5% year-over-year; full-year revenue rose 0.4%.

• Operating income for Q4 was CAD 26.7 million, down 4.7% year-over-year; full-year operating income was CAD 94.0 million, down 2.2%.

• Net income for Q4 was CAD 17.5 million (CAD 0.44 per share diluted), down 5.6% year-over-year; full-year net income was CAD 64.5 million (CAD 1.58 per share diluted), down 2.5%.

• Canadian Specialized Transportation Network and logistics/distribution product lines showed continued growth, with packaging solutions rebounding strongly in Q4.

Financial highlights

• Q4 healthcare logistics segment revenue rose 10.4% year-over-year to CAD 48.7 million, with logistics/distribution up 9.2% and packaging up 25.2%.

• Specialized transportation segment revenue was CAD 119.6 million, down 4.3% year-over-year, mainly due to U.S. truckload declines and lower fuel surcharges.

• Q4 EBITDA was CAD 43.6 million (25.9% margin), down 2.7% year-over-year; full-year EBITDA was CAD 164.6 million (25.3% margin), up 0.5%.

• Full-year EPS increased to CAD 1.58 (diluted) from CAD 1.55, aided by share buybacks.

• Cost of transportation and services in Q4 was 49.6% of revenue, down from 50.7% a year ago.

Outlook and guidance

• Canadian business expected to maintain mid- to high-single-digit growth, supported by stable healthcare demand and demographic trends.

• U.S. operations remain challenged but are undergoing integration and cost discipline, with expectations for stabilization and modest growth by year-end.

• 2025 organic growth rate in the 4%-7% range is considered achievable.